Rep. April McClain Delaney Sells IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock

Posted by Scott Moore on Nov 6th, 2025

Representative April McClain Delaney (D-Maryland) recently sold shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX). In a filing disclosed on November 04th, the Representative disclosed that they had sold between $1,001 and $15,000 in IDEXX Laboratories stock on October 16th.

Representative April McClain Delaney also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Teledyne Technologies (NYSE:TDY) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Fortune Brands Innovations (NYSE:FBIN) on 10/31/2025.
Purchased $1,001 – $15,000 in shares of Brown & Brown (NYSE:BRO) on 10/31/2025.
Purchased $1,001 – $15,000 in shares of Labcorp (NYSE:LH) on 10/31/2025.
Purchased $1,001 – $15,000 in shares of Tractor Supply (NASDAQ:TSCO) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Fortune Brands Innovations (NYSE:FBIN) on 10/29/2025.
Purchased $1,001 – $15,000 in shares of Brown & Brown (NYSE:BRO) on 10/29/2025.
Purchased $1,001 – $15,000 in shares of Labcorp (NYSE:LH) on 10/29/2025.
Sold $1,001 – $15,000 in shares of Middleby (NASDAQ:MIDD) on 10/22/2025.
Purchased $15,001 – $50,000 in shares of Nasdaq (NASDAQ:NDAQ) on 10/22/2025.

IDEXX Laboratories Stock Down 0.3%

IDXX stock opened at $720.21 on Thursday. The firm has a market cap of $57.62 billion, a PE ratio of 59.97, a P/E/G ratio of 4.06 and a beta of 1.62. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $735.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. The firm has a 50 day simple moving average of $642.72 and a 200 day simple moving average of $575.17.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last announced its quarterly earnings data on Monday, November 3rd. The company reported $3.40 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.26. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The company’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 1,200 shares of IDEXX Laboratories stock in a transaction on Monday, August 11th. The shares were sold at an average price of $656.53, for a total value of $787,836.00. Following the completion of the sale, the executive vice president owned 16,807 shares of the company’s stock, valued at approximately $11,034,299.71. The trade was a 6.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael G. Erickson sold 406 shares of the company’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $649.96, for a total transaction of $263,883.76. Following the completion of the sale, the executive vice president owned 11,287 shares of the company’s stock, valued at $7,336,098.52. This represents a 3.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 9,243 shares of company stock worth $6,018,650. Company insiders own 0.98% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on IDXX. BTIG Research upped their target price on IDEXX Laboratories from $785.00 to $830.00 and gave the company a “buy” rating in a report on Tuesday. Wall Street Zen downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Sunday, September 28th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of IDEXX Laboratories in a research note on Wednesday, October 8th. Morgan Stanley lifted their target price on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, Leerink Partners set a $785.00 price target on shares of IDEXX Laboratories in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $730.50.

Get Our Latest Report on IDEXX Laboratories

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of IDXX. Vanguard Group Inc. lifted its holdings in shares of IDEXX Laboratories by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 9,855,937 shares of the company’s stock valued at $4,139,001,000 after buying an additional 146,427 shares during the last quarter. Geode Capital Management LLC increased its holdings in IDEXX Laboratories by 2.3% in the second quarter. Geode Capital Management LLC now owns 2,464,290 shares of the company’s stock worth $1,317,875,000 after buying an additional 54,402 shares during the last quarter. Bank of New York Mellon Corp raised its position in IDEXX Laboratories by 41.7% during the third quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company’s stock valued at $1,313,992,000 after acquiring an additional 605,290 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in IDEXX Laboratories by 71.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company’s stock valued at $835,244,000 after acquiring an additional 825,965 shares during the last quarter. Finally, Principal Financial Group Inc. grew its position in IDEXX Laboratories by 16.7% in the third quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock worth $840,638,000 after acquiring an additional 187,967 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

IDEXX Laboratories Company Profile

(Get Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.